Skip to content
2000
Volume 7, Issue 5
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Recent evidence has suggested improved outcomes following incorporation of intraperitoneal chemotherapy administration with intravenous systemic chemotherapy as first-line treatment of small volume residual epithelial ovarian cancer. This review focuses on the mechanism of actions of the chemotherapeutic drugs and reviews the possible reasons for the superior outcomes of intraperitoneal chemotherapy.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955707780619644
2007-05-01
2025-09-13

  • From This Site

    /content/journals/mrmc/10.2174/138955707780619644
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955707780619644
Loading

  • Article Type:     Research Article
Keyword(s): carboplatin; cisplatin; Intraperitoneal chemotherapy; ovarian cancer management; paclitaxel

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test